150 related articles for article (PubMed ID: 11418632)
1. Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor.
Cairns CM; Gordon JR; Li F; Baca-Estrada ME; Moyana T; Xiang J
J Immunol; 2001 Jul; 167(1):57-65. PubMed ID: 11418632
[TBL] [Abstract][Full Text] [Related]
2. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
3. Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin.
Huang H; Li F; Cairns CM; Gordon JR; Xiang J
Biochem Biophys Res Commun; 2001 Feb; 281(2):378-82. PubMed ID: 11181058
[TBL] [Abstract][Full Text] [Related]
4. Adenoviral-mediated gene transfer of lymphotactin to the lungs of mice and rats results in infiltration and direct accumulation of CD4+, CD8+, and NK cells.
Emtage PC; Xing Z; Wan Y; Zlotnik A; Graham FL; Gauldie J
J Interferon Cytokine Res; 2002 May; 22(5):573-82. PubMed ID: 12060496
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors.
Huang H; Liu Y; Xiang J
Cell Immunol; 2002; 217(1-2):12-22. PubMed ID: 12425997
[TBL] [Abstract][Full Text] [Related]
6. Vaccine of engineered tumor cells secreting stromal cell-derived factor-1 induces T-cell dependent antitumor responses.
Shi M; Hao S; Su L; Zhang X; Yuan J; Guo X; Zheng C; Xiang J
Cancer Biother Radiopharm; 2005 Aug; 20(4):401-9. PubMed ID: 16114988
[TBL] [Abstract][Full Text] [Related]
7. Combined chemokine and cytokine gene transfer enhances antitumor immunity.
Dilloo D; Bacon K; Holden W; Zhong W; Burdach S; Zlotnik A; Brenner M
Nat Med; 1996 Oct; 2(10):1090-5. PubMed ID: 8837606
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.
Huang H; Xiang J
Int J Cancer; 2004 May; 109(6):817-25. PubMed ID: 15027114
[TBL] [Abstract][Full Text] [Related]
9. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
10. Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis.
Blaschke S; Middel P; Dorner BG; Blaschke V; Hummel KM; Kroczek RA; Reich K; Benoehr P; Koziolek M; Müller GA
Arthritis Rheum; 2003 Jul; 48(7):1858-72. PubMed ID: 12847680
[TBL] [Abstract][Full Text] [Related]
11. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
[TBL] [Abstract][Full Text] [Related]
12. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
Huang H; Bi XG; Yuan JY; Xu SL; Guo XL; Xiang J
Gene Ther; 2005 Jun; 12(12):999-1010. PubMed ID: 15789061
[TBL] [Abstract][Full Text] [Related]
13. Staphylococcal superantigens induce lymphotactin production by human CD4+ and CD8+ T cells.
Tikhonov I; Kitabwalla M; Wallace M; Malkovsky M; Volkman B; Pauza CD
Cytokine; 2001 Oct; 16(2):73-8. PubMed ID: 11683588
[TBL] [Abstract][Full Text] [Related]
14. Role of C chemokine lymphotactin in mediating recruitment of antigen-specific CD62L(lo) cells in vitro and in vivo.
Kurt RA; Bauck M; Harma S; McCulloch K; Baher A; Urba WJ
Cell Immunol; 2001 May; 209(2):83-8. PubMed ID: 11446740
[TBL] [Abstract][Full Text] [Related]
15. Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo.
Hedrick JA; Saylor V; Figueroa D; Mizoue L; Xu Y; Menon S; Abrams J; Handel T; Zlotnik A
J Immunol; 1997 Feb; 158(4):1533-40. PubMed ID: 9029087
[TBL] [Abstract][Full Text] [Related]
16. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma.
Rousseau RF; Haight AE; Hirschmann-Jax C; Yvon ES; Rill DR; Mei Z; Smith SC; Inman S; Cooper K; Alcoser P; Grilley B; Gee A; Popek E; Davidoff A; Bowman LC; Brenner MK; Strother D
Blood; 2003 Mar; 101(5):1718-26. PubMed ID: 12406881
[TBL] [Abstract][Full Text] [Related]
17. Lymphotactin acts as an innate mucosal adjuvant.
Lillard JW; Boyaka PN; Hedrick JA; Zlotnik A; McGhee JR
J Immunol; 1999 Feb; 162(4):1959-65. PubMed ID: 9973465
[TBL] [Abstract][Full Text] [Related]
18. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.
Zhang W; He L; Yuan Z; Xie Z; Wang J; Hamada H; Cao X
Hum Gene Ther; 1999 May; 10(7):1151-61. PubMed ID: 10340547
[TBL] [Abstract][Full Text] [Related]
19. The C-class chemokine, lymphotactin, impairs the induction of Th1-type lymphokines in human CD4(+) T cells.
Cerdan C; Serfling E; Olive D
Blood; 2000 Jul; 96(2):420-8. PubMed ID: 10887101
[TBL] [Abstract][Full Text] [Related]
20. Lymphotactin: a cytokine that represents a new class of chemokine.
Kelner GS; Kennedy J; Bacon KB; Kleyensteuber S; Largaespada DA; Jenkins NA; Copeland NG; Bazan JF; Moore KW; Schall TJ
Science; 1994 Nov; 266(5189):1395-9. PubMed ID: 7973732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
